Jaye Thompson Buys 1,000 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Jaye Thompson purchased 1,000 shares of the business’s stock in a transaction on Thursday, July 18th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $16,000.00. Following the purchase, the vice president now owns 261,348 shares of the company’s stock, valued at $4,181,568. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Greenwich LifeSciences Stock Up 2.9 %

Greenwich LifeSciences stock opened at $16.04 on Wednesday. Greenwich LifeSciences, Inc. has a 52-week low of $7.58 and a 52-week high of $21.44. The firm has a fifty day moving average of $15.18 and a 200-day moving average of $13.90. The firm has a market capitalization of $206.60 million, a P/E ratio of -22.28 and a beta of 1.64.

Greenwich LifeSciences (NASDAQ:GLSI) last released its quarterly earnings data on Monday, May 20th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.01. On average, research analysts expect that Greenwich LifeSciences, Inc. will post -0.75 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $36.00 price objective on shares of Greenwich LifeSciences in a research report on Wednesday, May 22nd.

Institutional Investors Weigh In On Greenwich LifeSciences

A hedge fund recently raised its stake in Greenwich LifeSciences stock. Vanguard Group Inc. boosted its position in shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) by 0.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 223,102 shares of the company’s stock after purchasing an additional 1,420 shares during the period. Vanguard Group Inc. owned approximately 1.73% of Greenwich LifeSciences worth $4,449,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 4.16% of the company’s stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.